KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
The call will feature presentations by Key Opinion Leaders (KOLs) Nancy Newman, MD (Emory Eye Center) and Sean Donahue, MD, PhD (Vanderbilt Children’s Hospital) who will discuss the current treatment landscape and unmet medical needs in Leber Hereditary Optic Neuropathy (LHON). Drs. Newman and Donahue will be available to answer questions at the conclusion of the call.
Additionally, GenSight’s management team will give an update on the company and discuss the results from the REVERSE and RESCUE Phase III trials for LUMEVOQ® (GS010). RESCUE and REVERSE are two separate randomized, double-masked, sham-controlled Phase III trials designed to evaluate the efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in subjects affected by LHON due to the G11778A mutation in the mitochondrial ND4 gene. LUMEVOQ® (GS010) is expected to be submitted for European approval in September 2020.
LUMEVOQ® (GS010) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a proprietary mitochondrial targeting sequence (MTS) technology platform developed from research conducted at the Institut de la Vision in Paris. The technology enables GS010 to use an engineered AAV (Adeno-Associated Virus) vector to address defects inside the mitochondria.
Dial-In & Webcast Information
- Domestic: 1-877-705-6003
- International: 1-201-493-6725
- Conference ID: 13705257
Q&A Information
If you would like to ask a question during the live Q&A, please submit your request via email : Email Q&AKOL Biographies
- Nancy Newman, MD
- Sean Donahue, MD, PhD
